Raymond James Financial
EBS icon

Raymond James Financial’s Emergent Biosolutions EBS Stock Holding History

Raymond James Financial’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,056
Closed -$91.8K – 5446
2026
Q1 		$91.8K Sell
11,056
-17,225
-61% -$178K ﹤0.01% 5054
2025
Q4 		$350K Buy
+28,281
New +$303K ﹤0.01% 4479
2025
Q3 		– Sell
-8,328
Closed -$53.1K – 5468
2025
Q2 		$53.1K Buy
+8,328
New +$47.7K ﹤0.01% 5160

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Raymond James Financial's EBS Position: Q2 2026 in Review

Raymond James Financial sold out of Emergent Biosolutions (EBS) in Q2 2026, closing a stake of 11,056 shares — an estimated $91.8K sold.

Raymond James Financial first reported a position in EBS in Q2 2025 and held it in 3 quarters. The position peaked at $350K in Q4 2025. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Raymond James Financial reported no remaining Emergent Biosolutions position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 11,056 Emergent Biosolutions shares in Q2 2026, an estimated $91.8K.
  • Raymond James Financial first reported a position in Emergent Biosolutions in Q2 2025 and held it in 3 quarters.
  • Raymond James Financial's Emergent Biosolutions position peaked at $350K in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.